Trial Profile
A Single-center Pilot Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Jun 2022
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Jun 2022 Primary endpoint has not been met (Frequency of acute cellular rejection over one year post-transplant) , according to Results published in the Clinical Transplantation
- 11 Jun 2022 Results published in the Clinical Transplantation
- 07 Jan 2021 Status changed from active, no longer recruiting to completed.